
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Department of Pharmacology, Cancer Institute, University of Pittsburgh, Pennsylvania 15213
Purpose and Experimental Design: To investigate a possible interaction between interleukin 10 (IL-10) and galectin-3 for protection of human breast carcinoma BT549 cells against liver ischemia-reperfusion-induced cytotoxicity, we used a liver/tumor coculture system. We also used IL-10-deficient C57BL/6 [IL-10(-/-)] mice and their wild-type C57BL/6 [IL-10(+/+)] mice to examine these interactions.
Results: More than 90% of galectin-3 cDNA-transfected BT549 cells (BT549-Gal3) survived after 24-h coculture with C57BL/6 [IL-10(+/+)] liver fragments isolated after ischemia. In contrast,
70% of control vector-transfected BT549 cells (BT549-Neo) showed metabolic death after culture with liver fragment. However, when the ischemic liver from IL-10 (-/-) mice was used, BT549-Gal3 did not exhibit enhanced survival against ischemia-reperfusion-induced cytotoxicity.
Conclusions: These data suggest that IL-10 and galectin-3 cooperatively interact to protect cells from ischemia-reperfusion injury.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |